Evidence map›Paper›PMID 28721592›Full record

ArticleMolecular biotechnology2017

Construction, Purification, and Characterization of a Homodimeric Granulocyte Colony-Stimulating Factor.

Gitana Mickiene, Indre Dalgediene, Zilvinas Dapkunas, Gintautas Zvirblis, Henrikas Pesliakas, Algirdas Kaupinis, Mindaugas Valius, Edita Mistiniene, Milda Pleckaityte

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Serum cytokines in periodontal diseases.Periodontology 2000 · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gitana MickieneInstitute of Biotechnology, Vilnius University, Sauletekio al. 7, 10257, Vilnius, Lithuania.
Indre DalgedieneInstitute of Biotechnology, Vilnius University, Sauletekio al. 7, 10257, Vilnius, Lithuania.
Zilvinas DapkunasInstitute of Biotechnology, Vilnius University, Sauletekio al. 7, 10257, Vilnius, Lithuania.
Gintautas ZvirblisInstitute of Biotechnology, Vilnius University, Sauletekio al. 7, 10257, Vilnius, Lithuania.
Henrikas PesliakasProfarma UAB, V.A. Graiciuno 6, 02241, Vilnius, Lithuania.
Algirdas KaupinisInstitute of Biochemistry, Vilnius University, Sauletekio al. 7, 10257, Vilnius, Lithuania.
Mindaugas ValiusInstitute of Biochemistry, Vilnius University, Sauletekio al. 7, 10257, Vilnius, Lithuania.
Edita MistinieneProfarma UAB, V.A. Graiciuno 6, 02241, Vilnius, Lithuania.
Milda PleckaityteInstitute of Biotechnology, Vilnius University, Sauletekio al. 7, 10257, Vilnius, Lithuania. milda.pleckaityte@bti.vu.lt.
Vilnius University · LT

Funding

Lietuvos Valstybinis Mokslo ir Studiju Fondas N-07006
6 · The paper itself

Abstract

Granulocyte colony-stimulating factor (G-CSF) has found widespread clinical application, and modified forms with improved biopharmaceutical properties have been marketed as well. PEGylation, the covalent modification of G-CSF with polyethylene glycol (PEG), has a beneficial effect on drug properties, but there are concerns connected to the immunogenicity of PEGylated compounds and bioaccumulation of the synthetic polymer. To overcome challenges connected with chemical modifications, we developed fusion proteins composed of two G-CSF molecules connected via different peptide linkers. Three different homodimeric G-CSF proteins were purified, and their in vitro and in vivo activities were determined. A G-CSF dimer, GCSF-Lα, was constructed using an alpha-helix-forming peptide linker, and it demonstrated an extended half-life in serum with a stronger neutrophil response as compared to the monomeric G-CSF protein. The GCSF-Lα protein, therefore, might be selected for further studies as a potential drug candidate.

Indexed as

AnimalsBiological AvailabilityCell LineGranulocyte Colony-Stimulating FactorHumansNeutrophilsPolyethylene GlycolsPolymersProtein Conformation, alpha-HelicalProtein MultimerizationRatsRecombinant Fusion ProteinsGranulocyte Colony-Stimulating FactorPolyethylene GlycolsPolymersRecombinant Fusion ProteinsAbsolute neutrophil countBiological activityBiopharmaceuticalsFusion proteinsG-CSFHalf-lifeLinkerProtein purification

Identifiers

PMID28721592
OpenAlexW2736642257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.